Talking Tox Webinars are commercially supported educational sessions highlighting case studies and relevant research by ACT Exhibitors and Supporters. 15 webinars took place during the live virtual Annual Meeting and are now available on-demand through February 15, 2022. Additional live webinars take place in January and will also be available on-demand through February 15. Please see the schedule below for details.

These webinars are available on-demand through February 15, 2022. You must be registered for the Annual Meeting to view the webinars.

Times listed are in Eastern Standard Time.

Monday, November 8, 2021

  • Case Studies: Adversity Level Determination in Nonclinical Toxicity Studies—A CRO Perspective

    • 12:00 Noon–1:00 PM

    Presented by: Altasciences

    Determination of adversity in nonclinical toxicity studies is a complex evaluation, exclusively based on professional opinions. NOAEL is commonly used to describe the outcome of a toxicity study and to communicate relevant risk to physicians and regulators. Examples will cover situations where overt toxicity, exaggerated pharmacology, and changes in various markers of toxicity are observed, in the context of other safety endpoints.

  • Elevate Your Toxicity Assays: New Models with Biological Relevance and Predictability

    • 12:00 Noon–1:00 PM

    Presented by: ATCC

    hTERT-immortalized primary cells exhibit the growth characteristics of continuous cell lines with physiological attributes of primary cells. Here, ATCC scientists discuss using hTERT-immortalized respiratory, skin, and kidney models in toxicological assays and present data demonstrating that they provide tissue-relevant results and reproducibility for any cell-based toxicity assay.

  • Direct CNS Delivery of Oligonucleotides: Beware of the Unexpected

    • 12:00 Noon–1:00 PM

    Presented by: Charles River

    As we gain more experience in the CNS ASO administration field, we are beginning to see unexpected scenarios arising despite using “well-understood” oligonucleotide backbones. Discussions will be centered on study designs, unexpected findings, and regulatory insight to consider when navigating those murky waters, including particular considerations for N=1 programs.

  • The Use of Minipigs in Juvenile Studies

    • 12:00 Noon–1:00 PM

    Presented by: Marshall BioResources

    Regulations for testing medicines and nutritional substances prior to human use are in a state of constant evolution, presently with a huge focus on pediatric use. There has been increased interest in and acceptance of the use of minipigs as a nonrodent species in toxicology and safety assessment for children.

  • Tuesday, November 9, 2021

  • Pharmaceutical Environmental Risk Assessment: Planning for Submission to the US FDA and EU EMA

    • 12:00 Noon–1:00 PM

    Presented by: Eurofins Regulatory Science Services

    Regulatory agencies, including the US FDA and EU EMA, have developed detailed guidance on how pharmaceutical products should be assessed for possible adverse environmental effects. The Environmental Risk Assessment (ERA) is required as part of the regulatory submission and marketing authorization for human and veterinary drugs. This course covers ERA testing and submission guidelines.

  • Today’s SEND Challenges: How to Overcome Them and Realize Tomorrow’s R&D Opportunities

    • 12:00 Noon–1:00 PM

    Presented by: Instem

    By working with customers from discovery through to regulatory approval, we are uniquely positioned to see the reality and potential for SEND. We will review the common challenges of SEND, give practical advice on overcoming these challenges, and discuss the opportunities arising from the standardization of nonclinical data.

  • Applications of Immune Cells and Cardiomyocytes in Drug Discovery

    • 12:00 Noon–1:00 PM

    Presented by: Stemcell Technologies Inc.

    Join us for a discussion on the applications of immune cells as well as PSC-derived cardiomyocytes in the drug discovery process. This session will focus on the use of various in vitro cell-based assays to evaluate therapy’s effect on highly relevant human cells in vitro. Additionally, we will explore how the Contract Assay Services division of STEMCELL Technologies can help you evaluate the potential toxic effects of your candidate therapeutics, including small molecule compounds and biologics.

  • Trends for Resource use in Drug Development: Origins, Supplies, Alternatives and the 3Rs

    • 12:00 Noon–1:00 PM

    Presented by: WuXi AppTec

    Learn more about the current trends in conducting and planning for NHP studies. By attending this presentation, you will learn about the differences in NHP strains and origins, current resource limitations, age and sexual maturity requirements, and the possible alternatives. Furthermore, the continued effort in the 3Rs will also be discussed.

  • Thursday, November 11, 2021

  • Reducing the Risk of Neurotoxicity—Trends and Future Outlook

    • 12:00 Noon–1:00 PM

    Presented by: Cyprotex

    The presentation will cover the latest 2D and 3D screening approaches in the field of neurotoxicity with an evaluation of MEA and 3D brain models and how these compare with existing technologies such as neurite outgrowth. Future direction in the use of transcriptomics will also be discussed.

  • Target Safety Assessments: How Augmented Intelligence Is Advancing Insights for Quicker, Evidence-Based Decision Making

    • 12:00 Noon–1:00 PM

    Presented by: Instem

    After completing several hundred Target Safety Assessments for our global clients, Instem is uniquely positioned to understand the challenges and opportunities associated with target modulation. We will present how augmented intelligence and advanced data mining technologies are now helping toxicologists make faster drug target decisions, while sharing insights on future trends.

  • Computational Approaches for Assessing Carcinogenic Potency of Nitrosamines

    • 12:00 Noon–1:00 PM

    Presented by: MultiCASE

    Nitrosamines pose varying degrees of cancer risk in the environment, in food, and as impurities in drugs. However, it is a difficult task to determine potency of untested nitrosamines. Lack of adequate in vivo and in vitro carcinogenicity assay data is certainly a major challenge, but at the same time, carcinogenicity risk of nitrosamines is considered to be related to their mutagenicity, metabolic profile, and physicochemical properties. Therefore, computational approaches are becoming a potential technique to relate structural features with carcinogenic potency.

  • Choosing the Right Model: Miniature Swine Model Selection Criteria for Toxicology and Pharmacology Studies

    • 12:00 Noon–1:00 PM

    Presented by: Sinclair Research

    Several different miniature swine models are commonly used as a second species in nonclinical research. This presentation will focus on the scientific rationale for miniature swine model selection, special considerations for toxicology and pharmacology study parameters, and comparative data of commonly used miniature swine strains.

  • Development of N-Nitrosamine Potency Classes to Support Regulatory Submissions

    • 1:30 PM–2:30 PM

    Presented by: Instem

    This session will outline recent developments in computational toxicology at Instem to support regulatory submissions, classification and labeling, and various R&D activities. This will include a review of recent updates to support the assessment of N-nitrosamine potency classes based on an extensive industry collaboration.

  • Safety of E-cig Products—A Toxicological Challenge

    • 1:30 PM–2:30 PM

    Presented by: Product Safety Labs

    An overview of the challenges to performing toxicity assessments for electronic cigarettes from the standpoint of in vivo exposure will be presented, ranging from model selection to atmosphere generation and pathology and molecular biology endpoints used to determine potential product toxicity and inform regulatory decision-making.

  • Novel Approach Methods in Genotoxicity and Developmental Toxicity Assessment

    • 1:30 PM–2:30 PM

    Presented by: Toxys

    Toxys has developed ToxTracker and ReproTracker, in vitro cell-based assays for chemical safety assessment with a focus on understanding the mode of action (MoA) of toxic compounds. In this session, we will address the latest developments and applications of these novel tools for the fields of genotoxicity and developmental toxicity.

  • Tuesday, January 11, 2022

  • Practical Considerations for a Cell Therapy Preclinical Program

    • 12:00 Noon–1:00 PM

    Presented by: Lovelace Biomedical

    The use of cell therapies has emerged as a powerful therapeutic approach with the potential to treat and even cure numerous diseases. This webinar will cover development of a successful preclinical safety program to support entry of a cell therapy into the clinic. This process requires a nimble approach where “one size” does not fit all and should be purpose-fit to the specific cell therapy approach.

  • Thursday, January 20, 2022

  • Best Practices for the Conduct of Preclinical Ototoxicity Evaluations

    • 12:00 Noon–1:00 PM

    Presented by: CBSET

    Ototoxicity resulting in inner ear damage is a common form of hearing loss. Current guidance for human drug development does not request auditory assessment, which has resulted in more than 200 ototoxic marketed medications. This webinar will provide a look into ototoxicity evaluation from screening to GLP studies with FDA guidelines.

  • To apply to host a Talking Tox Webinar please contact Liz Kasabian. Limited slots are available.

A Special Thank You to Our Platinum and Gold Sponsors

See all supporters here